JW Pharmaceutical (JWP) and LEO Pharma have signed a global licensing agreement for JWP’s novel atopic dermatitis drug candidate, JW1601, under which, LEO Pharma, a global leader in medical dermatology, will gain the exclusive rights to develop and commercialize JW1601 globally excluding Korea where JWP will maintain its exclusivity.  JWP will receive $17 million as upfront fee and milestones up to $385 million. Therefore, JWP will receive a total of up to $402 million which is equivalent to...